Ticagrelor was associated with a significantly higher 1-year myocardial infarction risk compared to clopidogrel and prasugrel in patients with coronary stent restenosis.
Does ticagrelor alter the 1-year risk of myocardial infarction compared to clopidogrel and prasugrel in patients with coronary stent restenosis?
In a real-world cohort of patients with coronary stent restenosis, ticagrelor was associated with a significantly higher 1-year risk of myocardial infarction compared to clopidogrel and prasugrel.
Absolute Event Rate: 0% vs 0%
In this real-world cohort of patients with coronary stent restenosis, ticagrelor was associated with a significantly higher 1-year MI risk compared to clopidogrel and prasugrel. These findings suggest potential differences in clinical outcomes among P2Y12 inhibitors in this high-risk setting and highlight the need for further prospective investigation to confirm these results.
Dhruva et al. (Sun,) reported a other. Ticagrelor was associated with a significantly higher 1-year myocardial infarction risk compared to clopidogrel and prasugrel in patients with coronary stent restenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: